U.S. markets closed

Canntab Therapeutics Limited (CTABF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.8240-0.0069 (-0.83%)
At close: 12:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8309
Open0.8400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.8169 - 0.8400
52 Week Range0.4500 - 0.8940
Volume4,250
Avg. Volume6,083
Market Cap29.44M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 08, 2016
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Canntab Receives Export License Approval from Health Canada
    PR Newswire

    Canntab Receives Export License Approval from Health Canada

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.

  • Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
    CNW Group

    Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia

    * 3rd Patent Grant with Australia following the United States and Canada * Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited * Participation in Australia's Largest Cannabis Research StudyTORONTO, March 9, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No.

  • Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.
    Newsfile

    Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.

    Toronto, Ontario--(Newsfile Corp. - March 3, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE:TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2nd (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape ...